氨酸:糖尿病心肌病的多方面调节剂
Muskan R Thakur1, Rashmi S Tupe1
1Symbiosis School of Biological Sciences (SSBS), Symbiosis International (Deemed University) (SIU), Lavale, Pune, 412115, Maharashtra, India.
Biochemical and biophysical research communications
|April 5, 2025
概括
补充L-氨酸 (L-Arg) 可以通过减少炎症,氧化应激和糖化来治疗糖尿病心肌病 (DCM). 这篇评论探讨了L-Arggg.
科学领域:
- 心血管医学 心血管医学
- 代谢障碍 代谢障碍 代谢障碍
- 分子生物学分子生物学
背景情况:
- 糖尿病会通过代谢失调引起糖尿病心肌病 (DCM),导致心肌重塑和损伤.
- DCM的主要病理特征包括加速糖化,氧化应激,炎症,心脏纤维化和高.
- 乱的L-氨酸 (L-Arg) 代谢和降低的细胞内L-Arg水平与DCM进展有关.
研究的目的:
- 审查L-氨酸 (L-Arg) 补充剂在治疗糖尿病心肌病 (DCM) 的治疗潜力.
- 阐明L-Arg影响DCM病理学的分子机制.
- 探索L-Arg补充对DCM患者的潜在临床结果.
主要方法:
- 对研究L-氨酸在糖尿病心肌病中的作用的文献综述.
- 分析受L-Arg影响的分子通路,包括糖化,氧化应激和炎症.
- 检查现有的临床数据和潜在的治疗应用.
主要成果:
- 氨酸 (L-Arg) 通过抑制糖化,氧化应激和炎症,对DCM表现出调节作用.
- 补充L-Arg可以缓解心肌纤维化,心肌缩和与DCM相关的亡.
- 恢复L-Arg新陈代谢和细胞内池显示出对抗DCM进展的前途.
结论:
- 补充L-氨酸 (L-Arg) 是糖尿病心肌病 (DCM) 的有希望的治疗策略.
- 了解L-Arg的分子机制可以指导其在心血管功能障碍中的临床应用.
- 对临床结果的进一步研究是有必要的,以确定L-Arg作为标准的DCM治疗.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
331
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
331
01:33Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
01:22Heart Failure Drugs: Diuretics
298
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
298
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
01:26Heart Failure Drugs: Inotropic Agents
445
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
445
01:28Nitric Oxide Signaling Pathway
4.9K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
4.9K